| Q38720538 | A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector |
| Q90383126 | Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging |
| Q42089523 | An Unusual Course of Metastatic Gastroesophageal Cancer |
| Q90948912 | Androgen deprivation therapy in men with node-positive prostate cancer treated with postoperative radiotherapy |
| Q46873895 | Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV? |
| Q38966736 | Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting. |
| Q38264014 | Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. |
| Q91967607 | Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review |
| Q49483598 | CCL5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment. |
| Q90207844 | Chemokine releasing particle implants for trapping circulating prostate cancer cells |
| Q41147905 | Comparing nodal versus bony metastatic spread using tumour phylogenies. |
| Q90292641 | Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer |
| Q38786508 | Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases |
| Q28552864 | Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis? |
| Q38722330 | Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies? |
| Q47549224 | Estimation of the Most Influential Factors for Survival Probability Prediction of Prostate Cancer Patients |
| Q92783709 | GRK2 enforces androgen receptor dependence in the prostate and prostate tumors |
| Q33440686 | Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach |
| Q35987354 | Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer |
| Q52676238 | How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data. |
| Q48370281 | Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. |
| Q52584764 | Metastases in Prostate Cancer. |
| Q49032788 | Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. |
| Q38598269 | New surgical approaches for clinically high-risk or metastatic prostate cancer |
| Q96768567 | Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression |
| Q38977428 | Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations |
| Q95843497 | Patterns of metastases of prostatic ductal adenocarcinoma |
| Q35971011 | Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer |
| Q61809700 | Prognostic Significance of Young Age and Non-Bone Metastasis at Diagnosis in Patients with Metastatic Prostate Cancer: a SEER Population-Based Data Analysis |
| Q92863168 | Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients |
| Q57130206 | Prognostic factors of oncologic outcomes in metastatic chemotherapy-naïve castration-resistant prostate cancer treated with enzalutamide in actual clinical practice in East Asia |
| Q90373559 | Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy |
| Q89997884 | Radioablation +/- hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159) |
| Q90322157 | Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis |
| Q37430019 | Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis |
| Q47115390 | Salvage lymph node dissection after 68Ga-PSMA or 18F-FEC PET/CT for nodal recurrence in prostate cancer patients |
| Q92564290 | Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells |
| Q92247747 | Site of extranodal metastasis impacts survival in patients with testicular germ cell tumors |
| Q40585481 | Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases |
| Q55519124 | Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. |
| Q36030759 | Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases |
| Q57106628 | Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence |
| Q92575358 | Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone |
| Q47273298 | The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation |
| Q41711657 | The outcome of prostate cancer patients treated with curative intent strongly depends on survival after metastatic progression |
| Q64102014 | The role of hormone therapy and chemotherapy in oligometastatic prostate cancer |
| Q41566002 | The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer |
| Q60960575 | Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer |
| Q54119488 | Tumor necrosis factor-α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation. |
| Q64296840 | UNC5D, suppressed by promoter hypermethylation, inhibits cell metastasis by activating death-associated protein kinase 1 in prostate cancer |
| Q91896916 | [Oligometastatic prostate cancer management] |